ReviewExpert review of vaccines2011
Vibrio cholerae: lessons for mucosal vaccine design.
Review in Expert review of vaccines, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 52 citations in OpenAlex.
- The Live Attenuated Cholera Vaccine CVD 103-HgR Primes Responses to the Toxin-Coregulated Pilus Antigen TcpA in Subjects Challenged with Wild-Type Vibrio cholerae.Clinical and vaccine immunology : CVI · 2017Trial
- Outer membrane vesicles inMicrobial cell (Graz, Austria) · 2026Article
- Mesenchymal Stem Cells and MSCs-Derived Extracellular Vesicles in Infectious Diseases: From Basic Research to Clinical Practice.Bioengineering (Basel, Switzerland) · 2022Review
- Article
- Immunomodulatory effects of mesenchymal stem cell-conditioned media on lipopolysaccharide of Vibrio cholerae as a vaccine candidate.Stem cell research & therapy · 2021Article
- Immunogenicity of cholera vaccination in children with inflammatory bowel disease.Human vaccines & immunotherapeutics · 2021Article
- Human gut-associated lymphoid tissues (GALT); diversity, structure, and function.Mucosal immunology · 2021Review
- Vibrio cholerae Outer Membrane Vesicles Inhibit Bacteriophage Infection.Journal of bacteriology · 2018Article
- Vibrio cholerae O1 secretes an extracellular matrix in response to antibody-mediated agglutination.PloS one · 2018Article
- Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2017Review
- Immunity Provided by an Outer Membrane Vesicle Cholera Vaccine Is Due to O-Antigen-Specific Antibodies Inhibiting Bacterial Motility.Infection and immunity · 2017Article
- Production of putative enhanced oral cholera vaccine strains that express toxin-coregulated pilus.PloS one · 2017Article
- Article
- Plant-based production of two chimeric monoclonal IgG antibodies directed against immunodominant epitopes of Vibrio cholerae lipopolysaccharide.Journal of immunological methods · 2015Article
- Rapid effects of a protective O-polysaccharide-specific monoclonal IgA on Vibrio cholerae agglutination, motility, and surface morphology.Infection and immunity · 2015Article
- A combined vaccine approach against Vibrio cholerae and ETEC based on outer membrane vesicles.Frontiers in microbiology · 2015Article
- Vaccines against human diarrheal pathogens: current status and perspectives.Human vaccines & immunotherapeutics · 2014Review
- Lipopolysaccharide modifications of a cholera vaccine candidate based on outer membrane vesicles reduce endotoxicity and reveal the major protective antigen.Infection and immunity · 2013Article
- Immunization with cholera toxin B subunit induces high-level protection in the suckling mouse model of cholera.PloS one · 2013Article
- Phase variable O antigen biosynthetic genes control expression of the major protective antigen and bacteriophage receptor in Vibrio cholerae O1.PLoS pathogens · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The ability of Vibrio cholerae to persist in bodies of water will continue to confound our ability to eradicate cholera through improvements to infrastructure, and thus cholera vaccines are needed. We aim for an inexpensive vaccine that can provide long-lasting protection from all epidemic cholera infections, currently caused by O1 or O139 serogroups. Recent insights into correlates of protection, epidemiology and pathogenesis may help us design improved vaccines. This notwithstanding, we have come to appreciate that even marginally protective vaccines, such as oral whole-cell killed vaccines, if widely distributed, can provide significant protection, owing to herd immunity. Further efforts are still required to provide more effective protection of young children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.